Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Key takeaways
Isomorphic Labs raised $5B in Series C funding to advance drug candidates to clinical trials, building on DeepMind's AI research.
- Series C funding co-led by Greenoaks and Sequoia Capital, with participation from new and existing investors.
- Company uses AI to design drugs, with positive preclinical results in oncology and immunology.
- Funding will support development of drug-design engine and expansion into more medicine types.
Summarised automatically by AI from the original article by TechCrunch. AI can make mistakes, so check the original for details.
Story details
- Published
- By
- Ram Iyer
- Section
- AI
- Length
- 297 words · about 1 min read
- Format
- Article
- Original
- techcrunch.com ↗








